Literature DB >> 7612554

Penetrating keratoplasty for pseudophakic corneal oedema.

J Kwartz1, B Leatherbarrow, P Dyer, A E Ridgway, A B Tullo.   

Abstract

AIMS: The study was designed to investigate the results of penetrating keratoplasty (PK) for pseudophakic corneal oedema (PCO).
METHODS: Retrospective analysis of 80 consecutive patients (82 eyes) who underwent PK for PCO between the years 1980-1992 with a minimum follow up of 12 months.
RESULTS: PKs for PCO have accounted for as many as 20% of all grafts performed in the hospital in recent years. The interval between cataract extraction and PK ranged from 6 to 161 months (mean 51 months). The intraocular lens was removed in 45 (55%), left in situ in 30 (37%), and exchanged in seven (8%) of cases respectively. Of the intraocular lenses involved 62% were iris supported, 31% angle supported, and 7% were posterior chamber lenses. Actuarial analysis shows graft survival to be 91% at 1 year and 86% at 2 years after surgery. The likelihood of graft survival was significantly enhanced by removal of the intraocular lens (p < 0.01). A corrected Snellen visual acuity worse than 6/60 was present in 36% of patients with a clear corneal graft. Ocular comfort was achieved in all patients with a clear corneal graft.
CONCLUSION: PK for PCO resulted in a disappointing visual result in a large proportion of patients. PK was, however, successful in relieving pain and corneal ulceration when present.

Entities:  

Mesh:

Year:  1995        PMID: 7612554      PMCID: PMC505130          DOI: 10.1136/bjo.79.5.435

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  27 in total

1.  Intraocular lens removal during penetrating keratoplasty for pseudophakic bullous keratopathy.

Authors:  M Busin; R C Arffa; M B McDonald; H E Kaufman
Journal:  Ophthalmology       Date:  1987-05       Impact factor: 12.079

2.  An update of the indications for penetrating keratoplasty. 1979 through 1983.

Authors:  J B Robin; J J Gindi; K Koh; D J Schanzlin; N A Rao; K K York; R E Smith
Journal:  Arch Ophthalmol       Date:  1986-01

3.  Complications of semiflexible, closed-loop anterior chamber intraocular lenses.

Authors:  P W Smith; S K Wong; W J Stark; J D Gottsch; A C Terry; R D Bonham
Journal:  Arch Ophthalmol       Date:  1987-01

4.  Posterior chamber intraocular lens implantation in the absence of posterior capsular support.

Authors:  W J Stark; G Goodman; D Goodman; J Gottsch
Journal:  Ophthalmic Surg       Date:  1988-04

5.  Penetrating keratoplasty for pseudophakic bullous keratopathy. Visual results.

Authors:  S R Waltman
Journal:  Arch Ophthalmol       Date:  1981-03

6.  Pseudophakic bullous keratopathy.

Authors:  E J Cohen; S E Brady; K Leavitt; M Lugo; M G Speaker; P R Laibson; J J Arentsen
Journal:  Am J Ophthalmol       Date:  1988-09-15       Impact factor: 5.258

7.  Intraocular lens replacement in pseudophakic bullous keratopathy.

Authors:  J R Hall; W S Muenzler
Journal:  Trans Ophthalmol Soc U K       Date:  1985

8.  Diurnal variation in vision after radial keratotomy.

Authors:  S MacRae; L Rich; D Phillips; R Bedrossian
Journal:  Am J Ophthalmol       Date:  1989-03-15       Impact factor: 5.258

9.  Changing indications for penetrating keratoplasty.

Authors:  P Haamann; O M Jensen; P Schmidt
Journal:  Acta Ophthalmol (Copenh)       Date:  1994-08

10.  [Pseudophakic bullous keratopathy].

Authors:  F Bigar; J Stürmer; R Ganzfried
Journal:  Klin Monbl Augenheilkd       Date:  1988-05       Impact factor: 0.700

View more
  2 in total

1.  Factors that influence the suitability of human organ-cultured corneas.

Authors:  T Röck; J Hofmann; S Thaler; M Bramkamp; K U Bartz-Schmidt; E Yoeruek; D Röck
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-08-20       Impact factor: 3.117

2.  Donor organ cultured corneal tissue selection before penetrating keratoplasty.

Authors:  V M Borderie; S Scheer; O Touzeau; F Vedie; S Carvajal-Gonzalez; L Laroche
Journal:  Br J Ophthalmol       Date:  1998-04       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.